|
GSK's Nucala gets FDA nod in asthma maintenance
BioWorld Online The FDA added another drug to the asthma armamentarium, with the approval of Glaxosmithkline plc's Nucala (mepolizumab) as a maintenance therapy for patients who have a history of severe asthma attacks despite being on treatment. Approval, disclosed … |
View full post on asthma – Google News